再生元制药公司(REGN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

REGN 再生元制药公司

休市中 05-03 16:00:00 EDT

957.00

+19.39

+2.07%

盘后957.00

+0.000.00%

19:29 EDT

最高958.13	最低926.94	成交量54.74万
今开926.94	昨收937.61	日振幅3.33%
总市值1,050亿	流通市值1,005亿	总股本1.10亿
成交额5.20亿	换手率0.52%	流通股本1.05亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"REGN","market":"US","secType":"STK","nameCN":"再生元制药公司","latestPrice":957,"timestamp":1714766400000,"preClose":937.61,"halted":0,"volume":547373,"hourTrading":{"tag":"盘后","latestPrice":957,"preClose":957,"latestTime":"19:29 EDT","volume":34701,"amount":33198321.7388,"timestamp":1714778944142},"delay":0,"floatShares":105000000,"shares":109761896,"eps":34.77,"marketStatus":"休市中","marketStatusCode":7,"change":19.39,"latestTime":"05-03 16:00:00 EDT","open":926.94,"high":958.13,"low":926.94,"amount":519822605.74281,"amplitude":0.033265,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":34.77,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1714982400000},"adr":0,"adjPreClose":937.61,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":929.79,"preClose":937.61,"latestTime":"09:15 EDT","volume":111,"amount":103156.44474,"timestamp":1714742148559},"postHourTrading":{"tag":"盘后","latestPrice":957,"preClose":957,"latestTime":"19:29 EDT","volume":34701,"amount":33198321.7388,"timestamp":1714778944142},"volumeRatio":0.8621608094680289},"requestUrl":"/m/hq/s/REGN/wiki","defaultTab":"wiki","newsList":[{"id":"2432902291","title":"坎托菲茨杰拉德公司：重申Regeneron Pharmaceuticals(REGN.US)评级，由中性调整至中性评级, 目标价925.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2432902291","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2432902291?lang=zh_cn&edition=full","pubTime":"2024-05-03 23:35","pubTimestamp":1714750511,"startTime":"0","endTime":"0","summary":"坎托菲茨杰拉德公司：重申Regeneron Pharmaceuticals(REGN.US)评级，由中性调整至中性评级, 目标价925.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050323351287ceca9c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050323351287ceca9c&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2432609911","title":"再生元制药公司公布截至一月的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2432609911","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2432609911?lang=zh_cn&edition=full","pubTime":"2024-05-02 21:32","pubTimestamp":1714656721,"startTime":"0","endTime":"0","summary":"   * Regeneron Pharmaceuticals Inc    公布的截至 1 月份的季度调整后每股收益为 9.55 美元，低于去年同期的每股收益 10.09 美元。华尔街预期为每股收益 8.56 美元至 11.62 美元。* Regeneron Pharmaceuticals Inc公布的本季度每股收益为6.27美元。* 公司报告的季度净收入为 7.22 亿美元。* Regeneron Pharmaceuticals Inc 本季度股价下跌了 6.1%，今年迄今为止上涨了 2.9%。* 华尔街对 Regeneron Pharmaceuticals Inc 的 12 个月目标价中位数为 1,060.00 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2432609665","title":"再生元制药公司跌0.25% 股价跌破900美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2432609665","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2432609665?lang=zh_cn&edition=full","pubTime":"2024-05-02 21:31","pubTimestamp":1714656706,"startTime":"0","endTime":"0","summary":"北京时间2024年05月02日21时31分，再生元制药公司股票出现异动，股价快速跳水0.25%。再生元制药公司股票所在的生物技术行业中，整体跌幅为0.55%。消息层面，截至21时31分，《Form 144 | 再生元制药公司高管拟出售250股股份，价值约22.24万美元》资讯为影响再生元制药公司的重要信息。此外，MARION E MCCOURT自2024年2月5日起至今合共已减持该公司1,608股股份，总价值约152.23万美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050221314787cb10d0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050221314787cb10d0&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2432678525","title":"Eylea和Dupixent销售疲软，Regeneron利润不及预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2432678525","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2432678525?lang=zh_cn&edition=full","pubTime":"2024-05-02 18:34","pubTimestamp":1714646079,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透5月2日 - 美国制药商Regeneron Pharmaceuticals Inc   周四公布的第一季度利润不及华尔街预期，原因是其大片眼药Eylea和湿疹治疗药物Dupixent的销售疲软。LSEG数据显示，不计入其他项目，该公司当季每股利润为9.55美元，而分析师预计为每股10.09美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2431465371","title":"Regeneron Pharmaceuticals Inc    预计每股收益 10.10 美元 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2431465371","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2431465371?lang=zh_cn&edition=full","pubTime":"2024-04-30 23:56","pubTimestamp":1714492570,"startTime":"0","endTime":"0","summary":"   * Regeneron Pharmaceuticals Inc    将于5月2日公布截至2024年3月31日的财报，预计该公司的季度收入将有所增长。* 根据LSEG的数据，21位分析师的平均预期显示，这家总部位于纽约Tarrytown的公司的营收将从去年同期的31.6亿美元增至32.21亿美元，增幅为1.9%。* LSEG 分析师对 Regeneron Pharmaceuticals Inc 的平均预期为每股收益 10.10 美元。* 华尔街对Regeneron Pharmaceuticals Inc的12个月目标价中位数为1060.00美元，高于其最新收盘价892.48美元。4月30日 - 上一季度业绩。除非另有说明，所有数字均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2430800302","title":"BUZZ-Regeneron 因大片药物收入不及预期而下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2430800302","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2430800302?lang=zh_cn&edition=full","pubTime":"2024-04-25 23:16","pubTimestamp":1714058181,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    4月25日 - ** Regeneron Pharmaceuticals   股价下跌3.3%，跌至3个月低点876.75美元。** 赛诺菲  是该公司湿疹和哮喘大片药物Dupixent的合作伙伴，该公司报告称 (link)，该药物第一季度的销售额为28.4亿欧元(，为30.4亿美元)。** 券商 Piper Sandler 和 TD Cowen 表示，Dupixent 的全球销售额低于华尔街预计的 31.7 亿美元** 年初至今，REGN 的股价基本持平 (1 美元 = 0.9334 欧元)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2430400210","title":"更新版 1-重发-研究发现艾伯维的皮肤病药物比 Regeneron 的 Dupixent 更有效","url":"https://stock-news.laohu8.com/highlight/detail?id=2430400210","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2430400210?lang=zh_cn&edition=full","pubTime":"2024-04-25 20:44","pubTimestamp":1714049048,"startTime":"0","endTime":"0","summary":"     路透社4月25日 - 艾伯维  周四称，在一项晚期头对头研究中，发现 其治疗一种炎症性皮肤病的药物Rinvoq比Regeneron Pharmaceuticals  和赛诺菲  的Dupixent更有效 。研究显示，在治疗16周后，Rinvoq帮助19.9%的患者同时实现了近乎完全的皮肤清除和无痒至微痒，而使用Dupixent治疗的患者只有8.9%。特应性皮炎是湿疹的一种特殊形式，是最常见的慢性炎症性皮肤病，其特点是皮肤瘙痒、干燥和发炎。2023 财年，Rinvoq 的全球销售收入为 39.7 亿美元，Dupixent 的全球销售收入为 115.9 亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2430047064","title":"研究显示艾伯维的 Rinvoq 优于 Regeneron 的 Dupixent","url":"https://stock-news.laohu8.com/highlight/detail?id=2430047064","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2430047064?lang=zh_cn&edition=full","pubTime":"2024-04-25 20:15","pubTimestamp":1714047318,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透社4月25日 - 艾伯维  周四称，其治疗一种炎症性皮肤病的药物Rinvoq在一项晚期头对头研究中显示出优于再生元制药  和赛诺菲  的Dupixent的疗效。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2429126921","title":"再生元制药公司涨0.86% 股价突破900美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2429126921","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2429126921?lang=zh_cn&edition=full","pubTime":"2024-04-22 21:32","pubTimestamp":1713792748,"startTime":"0","endTime":"0","summary":"北京时间2024年04月22日21时32分，再生元制药公司股票出现波动，股价急速拉升0.86%。截至发稿，该股报904.54美元/股，成交量5042股，换手率0.00%，振幅0.00%。最近的财报数据显示，该股实现营业收入131.17亿美元，净利润39.54亿美元，每股收益37.05美元，毛利108.73亿美元，市盈率26.01倍。再生元制药公司股票所在的生物技术行业中，整体涨幅为0.53%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042221322887a19640&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042221322887a19640&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428528706","title":"再生元制药公司涨2.64% 股价突破900美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2428528706","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2428528706?lang=zh_cn&edition=full","pubTime":"2024-04-19 21:31","pubTimestamp":1713533468,"startTime":"0","endTime":"0","summary":"北京时间2024年04月19日21时31分，再生元制药公司股票出现异动，股价急速拉升2.64%。截至发稿，该股报917.58美元/股，成交量3.7379万股，换手率0.03%，振幅0.46%。最近的财报数据显示，该股实现营业收入131.17亿美元，净利润39.54亿美元，每股收益37.05美元，毛利108.73亿美元，市盈率26.39倍。机构评级方面，在所有29家参与评级的机构中，69%的券商给予买入建议，24%的券商给予持有建议，7%的券商给予卖出建议。再生元制药公司股票所在的生物技术行业中，整体涨幅为1.15%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404192131088795f3fc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404192131088795f3fc&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427827066","title":"再生元制药公司涨0.22% 股价突破900美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2427827066","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2427827066?lang=zh_cn&edition=full","pubTime":"2024-04-16 21:34","pubTimestamp":1713274441,"startTime":"0","endTime":"0","summary":"北京时间2024年04月16日21时34分，再生元制药公司股票出现异动，股价快速拉升0.22%。截至发稿，该股报900.57美元/股，成交量1.0369万股，换手率0.01%，振幅0.33%。最近的财报数据显示，该股实现营业收入131.17亿美元，净利润39.54亿美元，每股收益37.05美元，毛利108.73亿美元，市盈率25.88倍。机构评级方面，在所有28家参与评级的机构中，71%的券商给予买入建议，21%的券商给予持有建议，8%的券商给予卖出建议。再生元制药公司股票所在的生物技术行业中，整体跌幅为0.50%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041621340187e80f85&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041621340187e80f85&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427985521","title":"更新版 1-Regeneron 将就司法部关于药品价格操纵的投诉进行辩护","url":"https://stock-news.laohu8.com/highlight/detail?id=2427985521","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2427985521?lang=zh_cn&edition=full","pubTime":"2024-04-16 07:59","pubTimestamp":1713225561,"startTime":"0","endTime":"0","summary":"     路透社4月15日 - Regeneron Pharmaceuticals   周一表示，该公司寻求对美国司法部指控其虚报黄斑变性药物Eylea平均销售价格的指控进行抗辩。\"Regeneron 在一份声明中说：\"向分销商报销信用卡服务费不是价格优惠，也不会影响 EYLEA 的价格。美国司法部上周在波士顿联邦法院提交的一份诉状中称， ，这家制药商多年来一直没有报告它是如何通过向药品分销商报销信用卡手续费的方式支付数亿美元来补贴Eylea的采购的。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2427858710","title":"Regeneron 将为美国司法部关于药物定价操纵的指控进行辩护","url":"https://stock-news.laohu8.com/highlight/detail?id=2427858710","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2427858710?lang=zh_cn&edition=full","pubTime":"2024-04-16 07:20","pubTimestamp":1713223210,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透社4月15日 - Regeneron Pharmaceuticals   周一表示，美国司法部对该公司虚报黄斑变性药物Eylea平均销售价格的指控 \"毫无根据\"，该公司计划在法庭上为此案辩护。司法部上周指控 (link) Regeneron 操纵了医疗保险的药品定价程序，夸大了其 Eylea 药物的平均销售价格。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2427620730","title":"再生元制药公司跌2.21% 股价跌破900美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2427620730","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2427620730?lang=zh_cn&edition=full","pubTime":"2024-04-13 00:32","pubTimestamp":1712939565,"startTime":"0","endTime":"0","summary":"北京时间2024年04月13日00时32分，再生元制药公司股票出现波动，股价大幅下挫2.21%。截至发稿，该股报900.00美元/股，成交量19.7375万股，换手率0.18%，振幅1.32%。再生元制药公司股票所在的生物技术行业中，整体跌幅为1.25%。消息层面，截至00时32分，《B of A Securities：维持Regeneron Pharmaceuticals评级，由低于大市调整至低于大市评级, 目标价由710.00美元调整至720.00美元。》资讯为影响再生元制药公司的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240413003245861e55a3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240413003245861e55a3&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426078967","title":"B of A Securities：维持Regeneron Pharmaceuticals(REGN.US)评级，由低于大市调整至低于大市评级, 目标价由710.00美元调整至720.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2426078967","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2426078967?lang=zh_cn&edition=full","pubTime":"2024-04-12 20:15","pubTimestamp":1712924147,"startTime":"0","endTime":"0","summary":"B of A Securities：维持Regeneron Pharmaceuticals(REGN.US)评级，由低于大市调整至低于大市评级, 目标价由710.00美元调整至720.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404122015528b1701ae&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404122015528b1701ae&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426762202","title":"美国研究综述-Cheesecake Factory、Netflix、Texas Roadhouse","url":"https://stock-news.laohu8.com/highlight/detail?id=2426762202","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2426762202?lang=zh_cn&edition=full","pubTime":"2024-04-12 15:04","pubTimestamp":1712905476,"startTime":"0","endTime":"0","summary":"    路透社4月12日 - 华尔街证券分析师周五调整了对几家美国上市公司的评级和目标价，其中包括 Cheesecake Factory、Netflix 和 Texas Roadhouse。要闻             * Cheesecake Factory Inc   ：斯蒂芬斯恢复覆盖，给予增持评级             * Netflix Inc   ：Piper Sandler将目标价从550美元上调至600美元             * Texas Roadhouse Inc   ：斯蒂芬斯恢复对该公司的研究，给予等权重评级 以下是路透社周五报道的美国公司研究报告摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2426319009","title":"加拿大皇家银行：重申Regeneron Pharmaceuticals(REGN.US)评级，由优于大市调整至优于大市评级, 目标价1189.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2426319009","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2426319009?lang=zh_cn&edition=full","pubTime":"2024-04-09 21:56","pubTimestamp":1712670971,"startTime":"0","endTime":"0","summary":"加拿大皇家银行：重申Regeneron Pharmaceuticals(REGN.US)评级，由优于大市调整至优于大市评级, 目标价1189.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240409215615875a40da&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240409215615875a40da&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422949519","title":"BUZZ-Regeneron 因 FDA 拒绝批准其血癌疗法而下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2422949519","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2422949519?lang=zh_cn&edition=full","pubTime":"2024-03-25 20:30","pubTimestamp":1711369819,"startTime":"0","endTime":"0","summary":"    3月25日 - ** 制药公司Regeneron Pharmaceuticals   股价盘前下跌约1.7%，至951美元** 该公司称， ，美国 FDA 拒绝批准其实验性血液癌症疗法 odronextamab 用于两种淋巴瘤的治疗。** 称 CRL 没有发现临床安全性或有效性、试验设计、标签或生产方面的任何问题** 补充说，公司正与 FDA 密切合作，并计划在今年晚些时候分享有关注册和监管时间表的最新信息** 截至上次收盘，公司股价在过去 12 个月中上涨了 18","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.regeneron.com","stockEarnings":[{"period":"1week","weight":0.0836},{"period":"1month","weight":0.0064},{"period":"3month","weight":0.0125},{"period":"6month","weight":0.1715},{"period":"1year","weight":0.2694},{"period":"ytd","weight":0.0896}],"compareEarnings":[{"period":"1week","weight":0.006},{"period":"1month","weight":-0.0156},{"period":"3month","weight":0.0343},{"period":"6month","weight":0.1762},{"period":"1year","weight":0.262},{"period":"ytd","weight":0.0757}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"再生元制药公司于1988年在纽约州成立。再生元制药公司是一家完全集成的生物技术公司，它发现、发明、开发、制造和商业化治疗严重疾病的药物。其正在开发的商业化药物和候选产品旨在帮助患有眼疾、过敏性和炎症性疾病、癌症、心血管和代谢性疾病、疼痛、传染病和罕见疾病的患者。它的核心业务战略是在基础科学研究和发现启用技术方面保持坚实的基础，并建立在临床开发、制造和商业能力的基础上。其目标是继续成为一家综合性、多产品的生物技术公司，为患者和医疗专业人员提供预防和治疗人类疾病的重要选择。","yearOnYearQuotes":[{"month":1,"riseRate":0.545455,"avgChangeRate":0.041845},{"month":2,"riseRate":0.393939,"avgChangeRate":0.089316},{"month":3,"riseRate":0.484848,"avgChangeRate":-0.042863},{"month":4,"riseRate":0.484848,"avgChangeRate":0.019407},{"month":5,"riseRate":0.647059,"avgChangeRate":0.063734},{"month":6,"riseRate":0.393939,"avgChangeRate":0.002817},{"month":7,"riseRate":0.636364,"avgChangeRate":0.053843},{"month":8,"riseRate":0.515152,"avgChangeRate":0.019343},{"month":9,"riseRate":0.484848,"avgChangeRate":0.029068},{"month":10,"riseRate":0.393939,"avgChangeRate":-0.00018},{"month":11,"riseRate":0.545455,"avgChangeRate":0.046018},{"month":12,"riseRate":0.515152,"avgChangeRate":0.048311}],"exchange":"NASDAQ","name":"再生元制药公司","nameEN":"Regeneron Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"再生元制药公司(REGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供再生元制药公司(REGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"再生元制药公司,REGN,再生元制药公司股票,再生元制药公司股票老虎,再生元制药公司股票老虎国际,再生元制药公司行情,再生元制药公司股票行情,再生元制药公司股价,再生元制药公司股市,再生元制药公司股票价格,再生元制药公司股票交易,再生元制药公司股票购买,再生元制药公司股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"再生元制药公司(REGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供再生元制药公司(REGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}